The Cancer Drug That Made Tumors Vanish in Every Single Patient
GSK's Jemperli just hit its primary endpoint in a rectal cancer trial, building on a streak where every single patient's tumor vanished without surgery. The implications for how we treat cancer are bigger than one drug.
Imagine your doctor telling you that you have locally advanced rectal cancer. The standard playbook is brutal: months of chemotherapy, weeks of radiation, then major surgery that often ends with a permanent colostomy bag. Your sex life, fertility, and daily routine may never be the same.
Now imagine a different conversation. Six months of an IV infusion, every three weeks. Then a scan. And the cancer is simply gone.
That's not a hypothetical. It's what GSK just confirmed in the AZUR-1 trial, and the results are turning heads across oncology.
A Perfect Score, Again
GSK announced this week that its PD-1 checkpoint inhibitor Jemperli (dostarlimab) met the primary endpoint in the Phase II AZUR-1 trial. The study enrolled patients with locally advanced rectal cancer whose tumors carry a specific molecular signature called dMMR/MSI-H (mismatch repair deficient/microsatellite instability-high). In plain English, these are tumors with so many DNA errors that they practically wear a neon sign saying "immune system, come get me."
The primary goal: sustained clinical complete response at 12 months, meaning no detectable cancer on MRI, endoscopy, or physical exam a full year after treatment. GSK reported a "clinically significant" rate of patients hitting that bar, though the company hasn't yet released exact percentages. Full data will come at an upcoming medical conference.
Safety looked clean too, consistent with what doctors have seen in prior dostarlimab studies. No new red flags.
But the real story here isn't one trial. It's the pattern.
The Streak That Started at Memorial Sloan Kettering
AZUR-1 is the sequel to one of the most jaw-dropping studies in recent cancer research. Back in 2022, Dr. Andrea Cercek and her team at Memorial Sloan Kettering published results in the New England Journal of Medicine that read like a typo. They gave dostarlimab to 12 patients with locally advanced dMMR rectal cancer. The result: 12 out of 12 achieved complete clinical response. A perfect 100%.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
No chemotherapy needed. No radiation. No surgery. No colostomy bags.
The medical world was skeptical (reasonably so; 12 patients is a tiny sample). But then the cohort grew. Fourteen patients, same result. By the latest published updates, all 42 rectal cancer patients who completed the six-month treatment course had their tumors disappear entirely. Not a single one needed chemo, radiation, or the surgeon's knife.
The median time to complete response was about 6.2 months, basically right at the end of the treatment course. Among the first 24 patients with longer follow-up, all had sustained complete clinical response for at least 12 months at a median follow-up of 26.3 months. Four patients have now been cancer-free for five years.
Think of it like a basketball player shooting free throws. Missing zero out of 42 isn't luck; it's telling you something fundamental about the matchup between this drug and this type of tumor.
Why These Tumors Are Immunotherapy's Dream Date
Not all rectal cancers respond this way. Only the ones with dMMR/MSI-H status do, and that's a relatively small slice of all rectal cancers (single-digit percentages). These tumors accumulate enormous numbers of mutations, which makes them terrible at hiding from the immune system. A PD-1 inhibitor like dostarlimab essentially removes the "don't attack me" disguise that cancer cells wear, letting immune cells do what they were built to do.
It's like removing the camouflage from a target at a shooting range. The immune system doesn't miss.
The flip side: tumors without this molecular profile don't respond nearly as well to checkpoint inhibitors alone. That's why universal dMMR/MSI-H testing in newly diagnosed rectal cancer patients is becoming critical. Miss the test, miss the opportunity.
What This Means for Patients (and for GSK)
The implications split into two buckets: clinical and commercial.
On the clinical side, this is nothing short of a paradigm shift for a specific group of patients. Standard treatment for locally advanced rectal cancer involves chemoradiation followed by surgery, often resulting in permanent changes to bowel, sexual, and reproductive function. If dostarlimab can reliably eliminate the need for all of that, the quality-of-life improvement is enormous. Several expert reviews now describe immunotherapy-first, non-operative management as the new standard of care for dMMR/MSI-H locally advanced rectal cancer at major academic centers.
That said, experts are careful to note the caveats. Follow-up is still maturing. No randomized trial has directly compared this approach to standard chemoradiation plus surgery. And if a patient doesn't achieve complete response, surgery remains the backup plan. The consensus in 2026: this works brilliantly in the right patients, but "right patients" is a carefully defined group.
On the commercial side, GSK is playing this smartly. The FDA has already granted Breakthrough Therapy Designation for dostarlimab in this exact setting, plus a prior Fast Track designation. That means an expedited path to a specific rectal cancer label, something no other PD-1 inhibitor currently has.
The Competitive Chess Match
GSK's Jemperli isn't the only PD-1 inhibitor on the market. Merck's pembrolizumab (Keytruda) and Bristol Myers Squibb's nivolumab (Opdivo) both have approvals in dMMR/MSI-H metastatic colorectal cancer. They're the established heavyweights.
But neither has prospective organ-preservation data in locally advanced rectal cancer that comes close to what dostarlimab has generated. That's GSK's wedge: not competing head-to-head in metastatic disease where Keytruda dominates, but owning a high-value niche where the data is uniquely compelling.
Analysts view this as a "high-value, low-volume" play. The eligible patient population is small because of the biomarker requirement. But the revenue per patient is significant, and the strategic halo effect for GSK's oncology credibility is substantial. One risk worth watching: if payers start viewing this as a generic PD-1 class effect, cheaper alternatives could undercut Jemperli. GSK's best defense is the label, the data, and the Breakthrough designation that ties the evidence specifically to dostarlimab.
The Bigger Picture
Zoom out, and the dostarlimab story is really about a question that's reshaping cancer treatment: when can immunotherapy replace surgery?
For decades, the answer was "never" in solid tumors. You cut it out, you blast it with radiation, you poison it with chemo. The immune system was an afterthought. The MSK trial shattered that assumption for one specific cancer type, and AZUR-1 just reinforced it in a larger, global patient population.
GSK already has a Phase III trial (AZUR-2) running in dMMR/MSI-H colon cancer, testing perioperative dostarlimab with event-free survival as the endpoint. If that reads out positively, the organ-preservation playbook could expand further into the GI tract.
We're still in the early chapters. Long-term survival data, randomized comparisons, and broader real-world experience will determine whether this becomes the undisputed standard. But 42 patients, zero failures, and no surgeries is a remarkable opening argument. The immune system, it turns out, was never an afterthought. It just needed someone to take the brakes off.
Deals & M&A
4 min read
Big Pharma Can't Stop Shopping in China
Chinese biotech companies inked $110 billion in out-licensing deals in just six months, a record that puts 2026 on pace to demolish last year's total. Every major Western pharma company is now shopping in China, and the carts keep getting bigger.
